Stefano Ferrari

Director
Chemotherapy for Musculoskeletal Tumors Unit
Orthopaedic Rizzoli Institute
Italy

Academician Orthopaedics
Biography

Attending Staff Physician, General Medicine Ward, Civil Hospital, Pavullo nel Frignano, Modena (7/16/85 - 8/21/88). Attending Staff Physician, General Medicine Ward, Civil Hospital, Vignola, Modena (8/22/88 - 1/31/89). Attending Staff Senior Physician, Chemotherapy for musculoskeletal tumors unit, Istituto Ortopedico Rizzoli, Bologna (2/1/89 - 12/6/1998). Director, Chemotherapy for musculoskeletal tumors unit, Istituti Ortopedici Rizzoli, Bologna (2004-present).

Research Intrest

Since 1989 he is actively interested in clinical research in the field of sarcomas of the musculo-skeletal system. He coordinates and participates to international and national collaborative projects for the treatment of Osteosarcomas and Erwing’s Sarcomas. He is in charge of the international protocol EUROBOSS (European Bone Over 40 Sarcoma Study) for the treatment of high-grade sarcomas with onset among patients over 40 years of age. In charge of the ISG/AIEOP EW 1 protocol for the treatment of non-metastatic Ewing’s sarcoma. In charge of the ISG Os-2 protocol for the treatment of non-metastatic osteosarcomas of limbs. In charge of the IGS Bone Sarcomas Committee. In charge of the Trial Steering Committee (TSC) of the international protocol EUROAMOS 1 (European American Osteosarcoma Study). Author of over 150 articles and scientific publications, prevalently on the topic of orthopedic oncology.

List of Publications
Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, Perani L, Innocenzi A, Galvez BG, Messina G, Morosetti R, Li S. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature cell biology. 2007 Mar 1;9(3):255-67.
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly T, Persohn E. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer research. 2000 Apr 15;60(8):2178-89.
Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007 Oct 19;131(2):324-36.